NCT03073369

Effect of Ergocalciferol on Iron Metabolism in Individuals With Chronic Kidney Disease

Targeting the Interactions Between Disordered Iron Homeostasis and Mineral Metabolism in Chronic Kidney Disease (Aim 1)

• Status: Withdrawn
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: University of Alabama at Birmingham · Academic / Other
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to learn more about how treatment with vitamin D can affect iron metabolism and blood levels of hepcidin (hormone controlling iron levels) in people with chronic kidney disease (CKD). Iron is an essential mineral which is a major component of proteins that carry oxygen in the blood. Problems with iron metabolism can lead to low blood levels (anemia), which can commonly happen in people with CKD. New research over the last decade has uncovered a new hormone called 'hepcidin', which is made in the liver and released into the blood. Hepcidin controls how much iron is in the blood by preventing the absorption of iron from food. Blood levels of hepcidin C are found to be high in people with CKD, and a recent small study in people with normal kidney function showed that treatment with vitamin D decreased hepcidin levels. In this study, investigators would like to examine the effects of vitamin D (Ergocalciferol) on iron metabolism and blood levels of hepcidin in individuals with CKD.

Conditions

• CKD
• Chronic Kidney Diseases
• Hepcidin
• Ergocalciferol
• Vitamin D
• Iron-deficiency
• Anemia

Interventions

Type	Name	Description
DRUG	Ergocalciferol 50000 UNT	Oral Ergocalciferol 50000 IU once daily for 6 weeks
DRUG	Placebo	Oral Placebo - one capsule once daily for 6 weeks

Timeline

• Start date: 2018-01-01
• Primary completion: 2018-12-01
• Completion: 2018-12-01
• First posted: 2017-03-08
• Last updated: 2018-03-15

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study